BackAlector Overview

Alector EBIT

Latest ebit for ALEC: $-120M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$22.86M
38.81% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$122.49M
11.07% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Alector (ALEC) FAQ

The latest EBIT for ALEC is $-120M as of June 2026. That compares with $-140M in the prior-year period — up 11.1% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Alector's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALEC's EBIT moved from $-140M to $-120M — a 11.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Alector's operating scale or balance-sheet position.

Against Healthcare companies, ALEC currently prints $-120M for EBIT, while the sector average sits near $22B. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Alector's growth, margins, and balance sheet.

A EBIT figure of $-120M for ALEC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting ALEC's EBIT ($-120M), review year-over-year change from $-140M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.